Which selective serotonin reuptake inhibitor (SSRI) is least likely to worsen restless leg syndrome (RLS)?

SSRI Least Likely to Worsen Restless Leg Syndrome

Sertraline appears to be the SSRI least likely to worsen restless leg syndrome, as it has weak dopamine reuptake inhibition properties that may theoretically mitigate RLS symptoms, unlike other SSRIs that more commonly trigger or exacerbate the condition.

Evidence-Based Reasoning

The 2025 AASM guidelines 1 do not specifically address SSRIs and RLS, focusing instead on primary RLS treatments. However, the research literature provides clear guidance on this clinical question.

Key Research Findings

Sertraline's Unique Profile:

• Sertraline is specifically identified as the SSRI providing "the least risk of RLS by blocking dopamine reuptake" 2
• This dopamine reuptake inhibition may actually "correct" dopaminergic dysfunction in RLS, unlike other SSRIs that worsen it 2

Comparative SSRI Risk Data: A prospective study of second-generation antidepressants found 3:

• Overall SSRI-induced RLS rate: 5-10% for most SSRIs (fluoxetine, paroxetine, citalopram, escitalopram)
• Sertraline falls within this range but has the theoretical advantage of dopamine reuptake blockade
• Mirtazapine had the highest risk at 28% (not an SSRI, but important comparator)
• Reboxetine had 0% incidence (also not an SSRI)

Systematic Review Conclusions: The 2018 systematic review 4 confirmed:

• Sertraline may increase periodic limb movements, but these do not disrupt sleep and are unlikely to be clinically significant
• Fluoxetine shows similar benign effects on PLMs
• Mirtazapine and venlafaxine (SNRI) carry higher RLS risk

Clinical Algorithm for SSRI Selection in RLS-Prone Patients

First-line choice:

• Sertraline - best evidence for lowest RLS risk among SSRIs

Second-line alternatives if sertraline fails:

• Fluoxetine - similar benign PLM profile to sertraline 4

Avoid in RLS patients:

• Citalopram - multiple case reports of severe RLS exacerbation 2
• Paroxetine - associated with RLS induction 3
• Escitalopram - 5-10% RLS risk 3

Non-SSRI considerations:

• Bupropion may actually reduce RLS symptoms short-term 4, though AASM guidelines suggest against its use for primary RLS treatment 1
• Mirtazapine should be strongly avoided (28% RLS risk) 3, 4

Important Clinical Caveats

Timing of RLS onset:

• RLS typically occurs during the initial days of antidepressant treatment 3
• Monitor closely in the first week after initiation

Risk factors for SSRI-induced RLS:

• Smoking significantly increases risk 5
• Pre-existing subclinical RLS may be unmasked
• Concomitant use of antipsychotics or calcium channel blockers may modify side effect profiles 5

Quality of life impact:

• Even when SSRIs induce RLS, the impact on quality of life can be substantial 5
• Early recognition and switching is preferable to adding RLS-specific medications

Emerging option:

• Vortioxetine (multimodal antidepressant) shows promise with potential RLS symptom regression in small case series 6, though more data needed

Practical Implementation

When prescribing antidepressants to patients with known RLS or at high risk:

1. Choose sertraline as first-line SSRI based on dopamine reuptake properties
2. Screen for RLS symptoms at baseline using IRLSSG criteria
3. Reassess within 3-7 days of initiation for new or worsening RLS
4. If RLS develops: discontinue immediately - symptoms typically resolve within 1-3 days 2, 7
5. Consider bupropion as alternative if depression treatment still needed, though monitor for other side effects

The evidence consistently points to sertraline having the most favorable profile among SSRIs for patients with or at risk for RLS, making it the clear choice when SSRI therapy is indicated 2, 4.